matrix metalloproteinase Archives • Fragile X Research

Matrix Metalloproteinase Therapeutic Treatments for Fragile X Syndrome

FRAXA Research Foundation 2012 Grants, 2013 Grants, Cheryl Gatto, PhD, Completed Research Grant, Disease Mechanisms, Drug Repurposing, Kendal Broadie, PhD, Treatment Targets, Vanderbilt University September 2, 2013April 25, 2018fruit fly, matrix metalloproteinase, minocycline

With a $157,000 grant from the FRAXA Research Foundation in 201202013, Dr. Kendal Broadie and Dr. Cheryl Gatto worked to define the distinct but also overlapping roles for MMP-1 and MMP-2 in synaptic structural and functional development. In drug studies with fragile X fruit flies, they will be testing a range of MMPIs in drug treatments to compare effectiveness during development and at maturity, in order to define the contributions of FXS developmental impairments and adult recovery/plasticity.

Role of Matrix Metalloproteinases in Fragile X

FRAXA Research Foundation 2006-2010 Grants, Completed Research Grant, Disease Mechanisms, Iryna Ethell, PhD, Tina Bilousova, PhD, Treatment Targets, University of California at Riverside February 2, 2009April 30, 2018matrix metalloproteinase, MMP9

With a $220,000 grant from FRAXA Research Foundation over 3 years, Dr. Iryna Ethell from the University of California at Riverside studied the regulation of dendritic structure by matrix metalloproteinases and other extracellular signaling pathways. This work identified a major treatment strategy for fragile X with the available MMP-9 inhibitor, minocycline.